NDAORALTABLETPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 29m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UKONIQ (umbralisib tosylate) is an oral small-molecule PI3K delta inhibitor approved by the FDA in February 2021. The specific indications and mechanism of action details are not provided in available data. It is administered as an oral tablet for patients requiring PI3K pathway inhibition.
Peak8.8 years to LOE
Product is in peak commercial phase with minimal competitive pressure, suggesting stable team size and focus on optimization rather than rapid growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only one linked job opportunity is identified for UKONIQ, suggesting a small or specialized team. Career roles are concentrated in commercial functions, indicating focus on sales, marketing, and revenue optimization rather than clinical or R&D expansion.
Trustee
Commercial
Worked on UKONIQ at TG Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.